Formulary Search
Search Results : Osteoporosis (Ibandronic acid - Osteoporosis)
Show Icon and Status Keys
- Tablets
150mg tablets
(note - 50mg tablets are not licensed for this indication)
- Intravenous infusion
- Tablets
ONCE WEEKLY tablets
ONCE DAILY tablets
- Oral solution
Reserve for patients with swallowing difficulties.
- Effervescent tablets
Reserve for patients who have tried alendronate and/or risedronate but are unable to swallow tablets (as opposed to patients with swallowing difficulties in whom the oral solution may be appropriate).
- Caplets
- Chewable tablets
- Effervescent tablets
- Tablets
AdcalD3/ AccreteD3 twice daily formulations are the preferred calcium and vitamin D supplements. Accrete D3 One a Day, Calci-D chewable tablets or theiCal-D3 chewable tablets are once daily options for patients with compliance issues.
- Tablets
Weekly tablets are 35mg. Daily tablets are 5mg.
NOTE - 30mg tablets are licensed for Paget's disease only
- Subcutaneous injection (sc)
Rheumatology only in secondary care.
Restricted to use in patients for whom bisphosphonates are unsuitable.
- Tablets
Only recommended as an option in secondary prevention where other options have been exhausted.
- Subcutaneous injection (sc)
- Injection
- Sachets (granules)
Rheumatology only. Reserved for severe osteoporosis in patients for whom other treatment options are not suitable.
- Injection
Post-menopausal osteoporosis in women. Rheumatology only.
See separate entry for use in men and juveniles.
Biosimilar teriparatide is recommended. Prescribe by brand.
- Intravenous infusion
5mg annual infusion
- Tablets
- Capsules